Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

Background/Aims: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide - is a candidate drug f...

Full description

Bibliographic Details
Main Authors:	Thomas Bernd Dschietzig, Katharina Krause-Relle, Maud Hennequin, Karoline von Websky, Jan Rahnenführer, Jana Ruppert, Hans Jürgen Grön, Franz Paul Armbruster, Ross A. D. Bathgate, Joerg R. Aschenbach, Wolf-Georg Forssmann, Berthold Hocher
Format:	Article
Language:	English
Published:	Karger Publishers 2015-03-01
Series:	Kidney & Blood Pressure Research
Subjects:	Diabetic nephropathy Diabetic cardiomyopathy Fibrosis Inflammation Relaxin
Online Access:	http://www.karger.com/Article/FullText/368484

Similar Items

Relaxin and related peptides : fifth international conference /
by: International Conference on Relaxin & Related Peptides (5th : 2008 : Maui, Hawaii), et al.
Published: (2009)

Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes
by: Hooi Hooi Ng, et al.
Published: (2018-05-01)

Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design
by: Annunziata D'Ercole, et al.
Published: (2022-08-01)

Receptor deorphanization in starfish reveals the evolution of relaxin signaling as a regulator of reproduction
by: Yuling Feng, et al.
Published: (2025-02-01)

Immunoexpression of Relaxin and Its Receptors in Stifle Joints of Dogs with Cranial Cruciate Ligament Disease
by: Brunella Restucci, et al.
Published: (2022-03-01)

Elucidation of relaxin-3 binding interactions in the extracellular loops of RXFP3
by: Ross eBathgate, et al.
Published: (2013-02-01)

Expression of Relaxin Family Peptide Receptors 1 and 3 in the Ovarian Follicle of Japanese Quail
by: Khoi X. Hoang, et al.
Published: (2024-02-01)

Characterizing relaxin receptor expression and exploring relaxin’s effect on tissue remodeling/fibrosis in the human bladder
by: Edward C. Diaz, et al.
Published: (2020-04-01)

Male Seminal Relaxin Contributes to Induction of the Post-mating Cytokine Response in the Female Mouse Uterus
by: Danielle J. Glynn, et al.
Published: (2017-06-01)

Development of Relaxin-3 Agonists and Antagonists Based on Grafted Disulfide-Stabilized Scaffolds
by: Han Siean Lee, et al.
Published: (2020-02-01)

Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism
by: Shuai Yuan, et al.
Published: (2023-04-01)

Relaxin receptors and nitric oxide synthases: search for the missing link
by: Bani Daniele, et al.
Published: (2003-02-01)

Relaxin inhibits patellar tendon healing in rats: a histological and biochemical evaluation
by: Tianpeng Xu, et al.
Published: (2019-07-01)

H3 Relaxin Alleviates Migration, Apoptosis and Pyroptosis Through P2X7R-Mediated Nucleotide Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation in Retinopathy Induced by Hyperglycemia
by: Kelaier Yang, et al.
Published: (2020-12-01)

Expression of Relaxin 3 in the Ovarian Follicle of Japanese Quail
by: Khoi X. Hoang, et al.
Published: (2023-10-01)

RELAXIN AND IMMUNE FACTORS AS PREDICTORS OF BIOLOGICAL PREPARATION FOR LABOUR
by: N.O. Shcherbina, et al.
Published: (2020-10-01)

Exploring the Use of Helicogenic Amino Acids for Optimising Single Chain Relaxin-3 Peptide Agonists
by: Han Siean Lee, et al.
Published: (2020-10-01)

Serum relaxin-3 and galanin levels in individuals with erectile dysfunction with and without type 2 diabetes mellitus
by: Umit Yilmaz, et al.
Published: (2024-04-01)

Anti-apoptotic and Matrix Remodeling Actions of a Small Molecule Agonist of the Human Relaxin Receptor, ML290 in Mice With Unilateral Ureteral Obstruction
by: Hooi Hooi Ng, et al.
Published: (2021-07-01)

The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease
by: Ting‐Yun Chen, et al.
Published: (2020-04-01)

Synthesis of fluorescent analogues of relaxin family peptides and their preliminary in vitro and in vivo characterization
by: Linda eChan, et al.
Published: (2013-12-01)

Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives
by: Sandra Feijóo-Bandín, et al.
Published: (2017-08-01)

The diverse influences of relaxin-like peptide family on tumor progression: Potential opportunities and emerging challenges
by: Jungchan Jung, et al.
Published: (2024-01-01)

Activation of Relaxin Family Receptor 1 from different mammalian species by relaxin peptide and small molecule agonist ML290
by: Zaohua eHuang, et al.
Published: (2015-08-01)

Relaxin-2 May Suppress Endometriosis by Reducing Fibrosis, Scar Formation, and Inflammation
by: Osamu Yoshino, et al.
Published: (2020-10-01)

Functional defects in adenylyl cyclase signaling mechanisms of insulin and relaxin in skeletal muscles of rat with streptozotocin type 1 diabetes
by: Shpakov Alexander, et al.
Published: (2006-12-01)

Liposomal Entrapment or Chemical Modification of Relaxin2 for Prolongation of Its Stability and Biological Activity
by: George Kogkos, et al.
Published: (2022-09-01)

Relaxin-Family Peptide Receptors 1 and 2 Are Fully Functional in the Bovine
by: Yanzhenzi Dai, et al.
Published: (2017-06-01)

Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension
by: Brian Martin, et al.
Published: (2021-07-01)

Experimental Static Cold Storage of the Rat Uterus: Protective Effects of Relaxin- or Erythropoietin-Supplemented HTK-N Solutions
by: Lina Jakubauskiene, et al.
Published: (2022-10-01)

Relaxin-3-deficient mice showed slight alteration in anxiety-related behavior
by: Yoshihisa eWatanabe, et al.
Published: (2011-08-01)

Relaxin-2 Prevents Erectile Dysfunction by Cavernous Nerve, Endothelial and Histopathological Protection Effects in Rats with Bilateral Cavernous Nerve Injury
by: Kang Liu, et al.
Published: (2023-04-01)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
by: Judit Simon, et al.
Published: (2019-06-01)

Relaxin peptides reduce cellular damage in cultured brain slices exposed to transient oxygen–glucose deprivation: an effect mediated by nitric oxide
by: Nicholas P. DeAdder, et al.
Published: (2021-02-01)

Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity
by: Tetsuya Kohsaka, et al.
Published: (2020-03-01)

Chemical synthesis of H2 relaxin analogue carrying an affinity tag through click chemistry-assisted diaminodiacid strategy
by: Yuan Gao, et al.
Published: (2025-03-01)

Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1
by: Anita A. Pinar, et al.
Published: (2020-08-01)

Relaxin treatment stimulates the differentiation of mesenchymal stem cells into osteoblasts
by: Lina M. Escobar, et al.
Published: (2023-10-01)

An Overview of Diabetic Nephropathy
by: Alp Atasoy, et al.
Published: (2015-03-01)

Relaxin-like Gonad-Stimulating Peptides in Asteroidea
by: Masatoshi Mita
Published: (2023-04-01)